Travere Therapeutics (TVTX)
(Delayed Data from NSDQ)
$9.49 USD
+0.77 (8.83%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $9.49 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TVTX 9.49 +0.77(8.83%)
Will TVTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TVTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TVTX
Travere (TVTX) Stock Jumps 5.2%: Will It Continue to Soar?
Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates
TVTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Key Metrics Tell Us About Travere (TVTX) Q1 Earnings
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
Analysts Estimate Arcturus Therapeutics (ARCT) to Report a Decline in Earnings: What to Look Out for
Other News for TVTX
Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Analysts Are Bullish on Top Healthcare Stocks: Mineralys Therapeutics, Inc. (MLYS), Teladoc (TDOC)
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Fortrea Holdings Inc. (FTRE) and Cellectis SA (CLLS)
Travere gains on Novartis data for Filspari rival, Calliditas buyout